Brief: Coiled Therapeutics Says AO-252 Dose Escalation On Track For Completion In H1 2026
08/04/2026 08:00
April 8 (Reuters) - Coiled Therapeutics PLC COIL.L: COILED THERAPEUTICS - CLINICAL TRIAL UPDATE COILED THERAPEUTICS PLC - TWICE-DAILY DOSING DELIVERS 80% CLINICAL BENEFIT RATE IN COHORT 4B COILED THERAPEUTICS PLC -AO-252 DOSE ESCALATION ON TRACK FOR COMPLETION IN H1 2026; NEXT-GEN FORMULATION MID-2026 Source text: ID:nRSH5358Za Further company coverage: COIL.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Coiled Therapeutics
See all newsRCS - Coiled Therapeutics - Investor Presentation via Engage Investor
RCS - Coiled Therapeutics - Participation in The Small Cap Showcase
Coiled Therapeutics - Director/PDMR Shareholding
Coiled Therapeutics - Interim Results to 30 June 2026
Coiled Therapeutics - Successful Enrolment Completed Across Two Cohorts